ERS Congress 2026: 6 Late-Breaking Trials to Know

The 2026 European Respiratory Society (ERS) Congress, held September 5 to 9 in Barcelona, Spain, delivered a late-breaking program with meaningful breadth across chronic obstructive pulmonary disease (COPD), asthma, idiopathic pulmonary fibrosis (IPF), and alpha-1 antitrypsin deficiency (AATD)— including the first phase 3 data for an IL-33 antagonist in COPD exacerbation prevention, early clinical results from a genetic correction program in AATD, and new findings on antifibrotic tolerability and novel cough mechanisms in IPF. Here are 6 late-breaking updates from the meeting that clinicians managing respiratory disease should know.